The power of EPKINLY makes remission possible

When you find out that your cancer has come back or hasn't responded after 2 or more types of treatment, you may be wondering what's next. Remission is still possible, and you have another option—one that is not chemotherapy or an infusion, and a treatment that you can start when you and your doctor are ready.

In a clinical study of 127 patients receiving EPKINLY, 82% (104 patients) achieved remission: complete remission in 60% (76 patients) and partial remission in 22% (28 patients).

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.

Two women reading a map while sitting on a park bench.

MY REASON WHY

EPKINLY is a different type of treatment 

  • EPKINLY is not an infusion, chemotherapy, or stem cell therapy
  • It is a bispecific antibody that is given as an injection when you need to start treatment
  • It is a treatment that harnesses the power of your own immune system to help fight cancer
T cell beside B cell.

How Bispecific Antibody Therapy Works

EPKINLY works by attaching to both your T cells and B cells, binding them together so that the T cells can attack and destroy B cells.

Two women reading a map in a park.

Some important things to keep in mind as you consider treatment

Your needs and priorities matter. You and your doctor can discuss these to help make treatment decisions.

Learn how quickly you may be able to start treatment. 

We're here to provide tools, resources, and support options.

Two men and woman sitting next to the pool.

Learn more about EPKINLY for the treatment of follicular lymphoma.